Related references
Note: Only part of the references are listed.The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
Liliana Montella et al.
CANCERS (2022)
Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
Anja C. Roden et al.
FRONTIERS IN ONCOLOGY (2022)
Imaging Evaluation of Thymoma and Thymic Carcinoma
Chad D. Strange et al.
FRONTIERS IN ONCOLOGY (2022)
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini et al.
EUROPEAN JOURNAL OF CANCER (2021)
State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma
Michael Ried et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study
Lukas Kirzinger et al.
PLOS ONE (2016)
Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT
William Makis et al.
CLINICAL NUCLEAR MEDICINE (2015)
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial
PJ Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)